@iammuneagain.bsky.social
Reposted
Good news! Early bird rates are now available until 14 November!
Don’t miss your chance to save on registration and join industry leaders from around the globe.
Secure your spot now and take advantage of the extended savings - vasculitis-melbourne2026.com/registration/
Don’t miss your chance to save on registration and join industry leaders from around the globe.
Secure your spot now and take advantage of the extended savings - vasculitis-melbourne2026.com/registration/
October 28, 2025 at 12:25 AM
Good news! Early bird rates are now available until 14 November!
Don’t miss your chance to save on registration and join industry leaders from around the globe.
Secure your spot now and take advantage of the extended savings - vasculitis-melbourne2026.com/registration/
Don’t miss your chance to save on registration and join industry leaders from around the globe.
Secure your spot now and take advantage of the extended savings - vasculitis-melbourne2026.com/registration/
Reposted
🚀 Interested in cellular therapy in #SLE? Join us!
Reuben Benjamin and I are hiring a Research Associate to join our translational research team at King’s College London 🔬
Help develop next-gen CAR-T therapies for autoimmune disease 💡
👉 www.kcl.ac.uk/jobs/127305-...
Reuben Benjamin and I are hiring a Research Associate to join our translational research team at King’s College London 🔬
Help develop next-gen CAR-T therapies for autoimmune disease 💡
👉 www.kcl.ac.uk/jobs/127305-...
Research Associate | King's College London
www.kcl.ac.uk
October 9, 2025 at 4:13 PM
🚀 Interested in cellular therapy in #SLE? Join us!
Reuben Benjamin and I are hiring a Research Associate to join our translational research team at King’s College London 🔬
Help develop next-gen CAR-T therapies for autoimmune disease 💡
👉 www.kcl.ac.uk/jobs/127305-...
Reuben Benjamin and I are hiring a Research Associate to join our translational research team at King’s College London 🔬
Help develop next-gen CAR-T therapies for autoimmune disease 💡
👉 www.kcl.ac.uk/jobs/127305-...
Reposted
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. buff.ly/gmn2vup
October 25, 2025 at 2:00 PM
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. buff.ly/gmn2vup
Reposted
Waning immunity. A significant Covid wave in England. No new variant.
Thanks Prof Pagel for highlighting and contextualizing
Thanks Prof Pagel for highlighting and contextualizing
October 10, 2025 at 2:41 PM
Waning immunity. A significant Covid wave in England. No new variant.
Thanks Prof Pagel for highlighting and contextualizing
Thanks Prof Pagel for highlighting and contextualizing
Reposted
